Navigation Links
ResMed Wins Initial Decision in ITC Patent Infringement Action
Date:8/24/2014

SYDNEY and SAN DIEGO, Aug. 24, 2014 /PRNewswire/ -- An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents.  As a result, ITC Judge Thomas Pender recommended that the ITC ban BMC and its U.S. distributor, 3B Medical, from importing or selling any of the infringing BMC products in the United States.  Judge Pender also recommended a cease and desist order that would enjoin BMC and 3B from selling, advertising, marketing, storing or testing the infringing products in the United States.  ResMed is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

Judge Pender found that BMC's InH2 humidifier, as well as original and redesigned versions of the following BMC masks infringe ResMed's patents:

  • iVolve nasal mask
  • iVolve N2 nasal mask
  • Willow nasal pillows mask
  • iVolve full face mask
  • "The Judge's decision is not just a victory for ResMed and the product innovation that is core to our brand, but it's also a win for patients who deserve high quality, comfortable care," said David Pendarvis, ResMed chief administrative officer and global general counsel. "We will continue innovating and continue protecting our intellectual property anywhere we identify infringement."

    About ResMed:
    ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative produc
    '/>"/>

    SOURCE ResMed
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2

    Related medicine technology :

    1. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
    2. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
    3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
    4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
    5. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
    7. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
    8. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    9. ResMed Takes Action to Enforce Patents
    10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    11. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, Inc. ... results from the  IAP310 study have been published ... a peer-reviewed journal with broad, multidisciplinary readership. ... evaluating the safety and efficacy of Zalviso, also ... (SSTS), for the treatment of post-operative pain in ...
    (Date:10/22/2014)... , Oct. 22, 2014  Regulus Therapeutics ... biopharmaceutical company leading the discovery and development ... that it has demonstrated human proof-of-concept with ... study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR ... hepatitis C virus infection ("HCV").  Interim results ...
    (Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( www.pneumrx.com ... today announced completion of enrollment in their RENEW Study, ... Study is the FDA-approved IDE pivotal trial for the ... It was anticipated that the study, which ... would take until the end of 2014 to enroll ...
    Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
    ... GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company ... on the early diagnosis and preventive treatment of cardiometabolic ... selected by Windhover as one of the "Top Biopharma ... This announcement is part of the conference event organized ...
    ... Pasteur, the vaccines division of the sanofi-aventis Group ... announced today the results of the Phase III ... Virus Vaccine) candidate compared to Fluzone (Influenza Virus ...  Data from the clinical trial assessing the immunogenicity ...
    Cached Medicine Technology:GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 2GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch' 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 2Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 3Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 4Sanofi Pasteur Presents Phase III Data on Intradermal Microinjection of Influenza Vaccine 5
    (Date:10/22/2014)... (PRWEB) October 22, 2014 Healthcare ... completing their continuing education at home or on-the-go ... access to 20 brand new, premium Seminar-on-Demand CE ... catalog of over 2,000 hours of ... customize their educational experience. With such a diverse ...
    (Date:10/22/2014)... Lintelus, Inc., an event software provider, announced ... will be speaking on the subject of “Event Technology ... 28, at the Holiday Inn in New York City. ... as a Tech Demo at 12:45pm, to educate event ... engaging event experience. , The Annual Meetings Technology Expo ...
    (Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
    (Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
    (Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
    Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
    ... global pharmaceutical giant Novartis bagged the contract to make ... vaccines. The $54.8 million contract// was finalised on Wednesday. ... million in federal contracts to fight a possible bird-flu ... also awarded contracts on Wednesday by the U.S. Department ...
    ... participate in a five-year study, to evaluate the risks of ... . ,Professor Lawrie Challis, an authority on mobile ... the Department of Health and the mobile phone industry. If ... of the study, which is expected to cost ?3 million. ...
    ... corporate downsizing not only affects those who lose jobs ... ,'Employees who remained in work after downsizing may ... said lead author Mika Kivimaki, from the Department of ... ,'In other words, enforced redundancies may boost mental ...
    ... failure, says a new study. // ,Gregg Fonarow ... of over 100,000 patients hospitalised because their heart condition was ... ,They found that the fatter the person, the less likely ... researchers reported their findings in the latest issue of the ...
    ... world were infected by HIV in each day of the year ... total, around 410,000 to 660,000 children under the age of 15 ... ,The report added that most of the children were infected ... half of the children infected last year would die of AIDS-related ...
    ... are becoming an increasingly important method for detecting malaria. ... a range of other strategies for controlling the disease ... insecticide-treated bed nets, indoor spraying against malaria-carrying mosquitoes and ... ,The tests are ideal for rural areas ...
    Cached Medicine News:Health News:Downsizing Affects All Workers 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 2Health News:New Tests Promise Rapid and Accurate Detection of Malaria 3
    Binocular indirect ophthalmic lenses. General diagnosis & treatment....
    ... Volk's super ... biomicroscopy lenses. Examination ... Provide unprecedented fundus ... addressing maximum potential ...
    ... series slit lamp biomicroscopy ... of the posterior pole. ... capability, specifically addressing maximum ... fundus image resolution & ...
    Volk indirect lenses. High magnification views of the posterior pole....
    Medicine Products: